Tamara Alagirova
CEO, Founder
MONCYTE Health
MONCYTE Health provides a laboratory‑based diagnostic test that quantifies lipid uptake and storage in monocytes to predict individual responses to cholesterol‑lowering therapy. By integrating this cellular analysis with risk assessment, the test helps cardiologists and primary‑care physicians identify patients who will not reach LDL‑C, Lp(a) or triglyceride targets with statins alone and recommends more effective combination treatments, reducing residual cardiovascular risk.
- Biotechnology
- Healthcare Technology
Updated 5 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Problem
Many patients with high cholesterol do not achieve optimal lipid levels with standard statin therapy, and clinicians lack tools to predict which individuals will benefit from additional or alternative lipid‑lowering treatments. This leads to residual cardiovascular risk and delayed prevention of heart attacks and strokes.
Solution
MONCYTE Health offers a personalized diagnostic test that quantifies lipid uptake and storage in immune cells, particularly monocytes, to assess individual biological responses to cholesterol‑lowering therapy. By measuring cellular lipid handling rather than traditional blood biomarkers, the test identifies patients who are unlikely to reach target LDL‑C, Lp(a), or triglyceride levels with statins alone. The resulting risk assessment and treatment recommendation enable clinicians to select more effective combination therapies early in the care pathway. This approach aims to accelerate achievement of lipid goals, reduce residual atherosclerotic risk, and support decision‑making as new lipid‑targeted drugs enter the market.
Target Audience
Primary customers are cardiologists, lipidologists, and primary‑care physicians managing patients with hypercholesterolemia and elevated cardiovascular risk.
Features
- Quantitative analysis of lipid uptake and storage in monocytes and other white blood cells
- Integrated risk assessment that predicts residual cardiovascular risk despite lipid‑lowering therapy
- Personalized treatment recommendations prioritizing combination therapies for high‑risk patients
- Ability to evaluate response to emerging therapies targeting Lp(a) and triglyceride‑rich lipoproteins
- Laboratory‑based assay that complements existing blood lipid panels without measuring additional blood substances